Terms: = Lung cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
439 results:
1. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract] [Full Text] [Related]
2. Targeting ret alterations in non-small cell lung cancer.
Nishikawa G; Klein MA
Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
[TBL] [Abstract] [Full Text] [Related]
3. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, ret fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
4. Association of Timely Comprehensive Genomic Profiling With Precision Oncology treatment Use and Patient Outcomes in Advanced Non-Small-Cell lung cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract] [Full Text] [Related]
5. [Intraductal carcinomas of the salivary glands: a clinicopathological and molecular genetic analysis of twenty-seven cases].
Sun Q; Sun JJ; Wang M; Zhang L; Zhang XW; Wei JG; Kong LF; Li J
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):250-256. PubMed ID: 38433052
[No Abstract] [Full Text] [Related]
6. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of first-line treatment options beyond ret-TKIs in advanced ret-rearranged non-small cell lung cancer: A multi-center real-world study.
Ge Y; Li J; Gong W; Wang J; Wei X; Liu J; Wang S; Wang L; Sun H; Cheng Q; Sun Y; Dang Q; Sun Y; Gao A
Cancer Med; 2024 Jan; 13(2):e6960. PubMed ID: 38349001
[TBL] [Abstract] [Full Text] [Related]
8. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract] [Full Text] [Related]
9. Response to immune checkpoint inhibitor combination therapy in metastatic ret-mutated lung cancer from real-world retrospective data.
Yan N; Zhang H; Shen S; Guo S; Li X
BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
[TBL] [Abstract] [Full Text] [Related]
10. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell lung cancer.
Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring
Dai M; Wang N; Xia Q; Liao Y; Cao W; Fan J; Zhou D; Wang S; Nie X
Front Immunol; 2023; 14():1258762. PubMed ID: 38235141
[TBL] [Abstract] [Full Text] [Related]
12. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract] [Full Text] [Related]
13. Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers.
Thorlund K; Duffield S; Popat S; Ramagopalan S; Gupta A; Hsu G; Arora P; Subbiah V
J Comp Eff Res; 2024 Mar; 13(3):e230147. PubMed ID: 38205741
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
Odintsov I; Sholl LM
Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive Genomic Analysis of Patients With Non-Small-Cell lung cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
[TBL] [Abstract] [Full Text] [Related]
16. Clinical evidence and adverse event management update of patients with ret- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract] [Full Text] [Related]
17. Strategies for mitigating adverse events related to selective ret inhibitors in patients with ret-altered cancers.
Nardo M; Gouda MA; Nelson BE; Barreto CMN; Slade JH; Poullard A; Zafereo M; Hu MI; Cabanillas ME; Subbiah V
Cell Rep Med; 2023 Dec; 4(12):101332. PubMed ID: 38118420
[TBL] [Abstract] [Full Text] [Related]
18. Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non-Small Cell lung cancer With BRAF, ERBB2/HER2, MET , or ret Alterations: A Systematic Literature Review.
Akers KG; Oskar S; Zhao B; Frederickson AM; Arunachalam A
J Immunother; 2024 May; 47(4):128-138. PubMed ID: 38112201
[TBL] [Abstract] [Full Text] [Related]
19. [Chinese expert consensus on the diagnosis and treatment of advanced ret fusion-positive non-small cell lung cancer (2023 edition)].
; ;
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
[TBL] [Abstract] [Full Text] [Related]
20. Whole-exome sequencing explored mechanism of selpercatinib resistance in ret-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
Peng Y; Zheng Z; Zewen W; Yanan L; Mingyan Z; Meili S
BMC Pulm Med; 2023 Dec; 23(1):492. PubMed ID: 38057798
[TBL] [Abstract] [Full Text] [Related]
[Next]